BRC452468_sm_Tables.pdf (179.17 kB)
Supplementary Material for: Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study
Version 2 2016-11-04, 08:17
Version 1 2016-11-04, 08:16
dataset
posted on 2016-11-04, 08:17 authored by Gaß P., Fasching P.A., Fehm T., de Waal J., Rezai M., Baier B., Baake G., Kolberg H.-C., Guggenberger M., Warm M., Harbeck N., Wuerstlein R., Deuker J.-U., Dall P., Richter B., Wachsmann G., Brucker C., Siebers J.W., Fersis N., Kuhn T., Wolf C., Vollert H.-W., Breitbach G.-P., Janni W., Landthaler R., Kohls A., Rezek D., Noesselt T., Fischer G., Henschen S., Praetz T., Heyl V., Kühn T., Krauss T., Thomssen C., Hohn A., Tesch H., Mundhenke C., Hein A., Rauh C., Bayer C.M., Jacob A., Schmidt K., Belleville E., Hadji P., Brucker S.Y., Beckmann M.W., Wallwiener D., Kümmel S., Löhberg C.R.Background: Decision-making for or against neoadjuvant or adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive breast cancer does not follow any clear guidelines, and some patients may unnecessarily undergo chemotherapy and be exposed to the associated toxicity. The aim of this study was to identify the patient population for whom this issue may bear relevance. Methods:Patients being treated with letrozole in the prospective multicenter noninterventional EvAluate-TM study were recruited. The percentage of patients receiving chemotherapy and factors associated with chemotherapy administration were identified. Results: In all, 3,924 (37.4%) patients received chemotherapy before treatment with letrozole. Of these, 293 (20%) underwent neoadjuvant therapy. Younger age was predictive for both adjuvant and neoadjuvant therapy. Overall, decisions in favor of administering chemotherapy are more likely to be made in patients with a higher body mass index (BMI), and neoadjuvant chemotherapy is administered at a higher rate in women with a lower BMI. Concomitant medication influenced the overall decision-making regarding chemotherapy, irrespective of whether it was given on a neoadjuvant or adjuvant basis. Conclusion: There is an ongoing debate as to whether all of the many patients who receive chemotherapy actually benefit from it. Neoadjuvant chemotherapy is frequently administered in this patient population, and this should encourage further research to resolve current clinical and research issues.
